Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA 1

Blood

Volumn 120, Issue 4, 2012, Pages 858-867

  Fang, Jing ^a   Rhyasen, Garrett ^a,b   Bolanos, Lyndsey ^a,b   Rasch, Christopher ^a   Varney, Melinda ^a   Wunderlich, Mark ^a   Goyama, Susumu ^a   Jansen, Gerrit ^c   Cloos, Jacqueline ^c   Rigolino, Carmela ^d   Cortelezzi, Agostino ^e   Mulloy, James C ^a   Oliva, Esther N ^d   Cuzzola, Maria ^d   Starczynowski, Daniel T ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; MESSENGER RNA; PROTEASOMAL SUBUNIT ALPHA 1; PROTEASOME; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHAGY; CYTOTOXICITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 84864495501     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-407999     Document Type: Article

References (52)

1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7(2):118-129. (Pubitemid 46164747)
2. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-4851.
3. Masonic Cancer Center, University of Minnesota. Bortezomib and vorinostat in treating patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. Available from: http://clinical trials.gov/ct2/show/NCT00818649. Accessed April 3, 2012.
4. Virginia Commonwealth University. Belinostat and bortezomib in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndrome. Available from: http://clinicaltrials.gov/ ct2/show/NCT01075425. Accessed April 3, 2012.
5. Children's Oncology Group. Bortezomib and combination chemotherapy in treating younger patients with recurrent, refractory, or secondary acute myeloid leukemia. Available from: http:// clinicaltrials.gov/ct2/show/NCT00666588. Accessed April 3, 2012.
6. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther. 2005;4(4):686-692. (Pubitemid 40601851)
7. Braun T, Carvalho G, Coquelle A, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107(3):1156-1165. (Pubitemid 43156318)
8. Dai Y, Chen S, Wang L, et al. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbation in NF-kappaB and Bim. Br J Haematol. 2011; 153(2):222-235.
9. Riccioni R, Senese M, Diverio D, et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to bortezomib-mediated apoptosis. Br J Haematol. 2007;139(2):194-205. (Pubitemid 47493077)
10. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-4916. (Pubitemid 43882644)
11. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24(22):9695- 9704. (Pubitemid 39458799)
12. Milani M, Rzymski T, Mellor HR, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib. Cancer Res. 2009;69(10):4415-4423.
13. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell. 2011;146(5):682-695.
14. Scott RC, Juhasz G, Neufeld TP. Direct induction of autophagy by Atg1 inhibits cell growth and induces apoptotic cell death. Curr Biol. 2007;17(1):1-11. (Pubitemid 46027564)
15. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49-58.
16. Rhyasen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia. 2012;26(1):13-22.
17. Starczynowski DT, Morin R, McPherson A, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood. 2011;117(2):595-607.
18. Starczynowski DT, Kuchenbauer F, Wegrzyn J, et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol. 2011; 39(2):167-178.
19. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(33):12481-12486. (Pubitemid 44267285)
20. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A. 2011;108(22):9184-9189.
21. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011; 208(6):1189-1201.
22. Hongming H, Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res. 2009;33(1):115-122.
23. Terpos E, Verrou E, Banti A, Kaloutsi V, Lazaridou A, Zervas K. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leuk Res. 2007;31(4):559-562. (Pubitemid 46198932)
24. Matsuoka A, Tochigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24(4):748-755.
25. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112(6):2489-2499.
26. Ng KP, Ebrahem Q, Negrotto S, et al. p53 independent epigenetic- differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. 2011;25(11):1739-1750.
27. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)
28. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108(1): 337-345. (Pubitemid 43990647)
29. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16): 1617-1628.
30. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33-47. (Pubitemid 43261977)
31. Belloni D, Veschini L, Foglieni C, et al. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res. 2010; 316(6):1010-1018.
32. Franke NE, Niewerth D, Assaraf YG, et al. Impaired bortezomib binding to mutant beta5 sub-unit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 2012;26(4):757-768.
33. Wu YT, Tan HL, Shui G, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem. 2010;285(14):10850-10861.
34. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008;103(1): 270-283.
35. Rückrich T, Kraus M, Gogel J, et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia. 2009;23(6): 1098-1105.
36. Skov V, Larsen ST, Thomassen M, et al. Increased expression of proteasome-related genes in patients with primary myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2010: Abstract 4117.
37. Lü S, Chen Z, Yang J, et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol. 2008; 36(10):1278-1284.
38. Balsas P, Galan-Malo P, Marzo I, Naval J. Bortezomib resistance in a myeloma cell line is associated to PSMbeta5 overexpression and polyploidy. Leuk Res. 2012;36(2):212-218.
39. Alimena G, Breccia M, Musto P, et al. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. Leuk Res. 2011;35(4):504- 507.
40. Natarajan-Ame S, Park S, Ades L, et al. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II study by the GFM. Br J Haematol. 2012;158(2):232-237.
41. Colado E, Alvarez-Fernandez S, Maiso P, et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica. 2008;93(1):57-66. (Pubitemid 351156152)
42. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008;111(4):2364-2373. (Pubitemid 351451445)
43. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 2002; 100(10):3553-3560. (Pubitemid 35303923)
44. Starczynowski DT, Lockwood WW, Delehouzee S, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest. 2011; 121(10):4095-4105.
45. Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325(5944):1134-1138.
46. Kawaguchi T, Miyazawa K, Moriya S, et al. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagylysosome and ER stress. Int J Oncol. 2011;38(3): 643-654.
47. Wu WK, Wu YC, Yu L, Li ZJ, Sung JJ, Cho CH. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochem Biophys Res Commun. 2008; 374(2):258-263.
48. Li L, Soetandyo N, Wang Q, Ye Y. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim Biophys Acta. 2009; 1793(2):346-353.
49. Inomata M, Niida S, Shibata KI, Into T. Regulation of Toll-like receptor signaling by NDP52-mediated selective autophagy is normally inactivated by A20. Cell Mol Life Sci. 2012;69(6):963-979.
50. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004;11(4):448- 457.
51. Zhu YX, Tiedemann R, Shi CX, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011;117(14): 3847-3857.
52. Li X, Wood TE, Sprangers R, et al. Effect of non-competitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst. 2010;102(14): 1069-1082.